Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

• Published in: British journal of ophthalmology 2004-10, Vol.88 (10), p.1295-1298
• Main Authors: Hamacher, T, Schinzel, M, Schölzel-Klatt, A, Neff, H-M, Maier, H, Schlaffer, G, Beausencourt, E, Jütte, M, Scholz, R, Lorger, C, Stewart, W C
• Format: Article
• Language: English
• Subjects: Aged; Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Biological and medical sciences; CAI; carbonic anhydrase inhibitors; Clinical medicine; Clinical Science - Extended Reports; Clinical trials; Compliance; Data analysis; Data collection; Drug Combinations; Drug dosages; Female; Glaucoma; Glaucoma and intraocular pressure; Glaucoma, Open-Angle - drug therapy; Glaucoma, Open-Angle - physiopathology; Humans; Hypertension; intraocular pressure; Intraocular Pressure - drug effects; IOP; latanoprost/timolol fixed combination; latanoprost/timolol maleate fixed combination; LTFC; Male; Medical sciences; Middle Aged; Ocular Hypertension - drug therapy; Ocular Hypertension - physiopathology; Ophthalmology; Prospective Studies; Prostaglandins F, Synthetic - adverse effects; Prostaglandins F, Synthetic - therapeutic use; Studies; Timolol - adverse effects; Timolol - therapeutic use; Treatment Failure; Treatment Outcome
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjo.2004.043232

Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC). Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months. Results: In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p